Viatris Inc. (VTRS) Operating Cash Flow CAGR:-2.48%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, Viatris Inc.'s Operating Cash Flow CAGR averages -8.00% over 3 years and 3.92% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash Viatris Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
VTRS Operating Cash Flow CAGR Chart
Viatris Inc. (VTRS)
VTRS Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
VTRS Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $2.30B | $2.32B | +$13.00M | +0.56% | +0.56% |
| 2024 | $2.80B | $2.30B | $-496.70M | -17.74% | -17.74% |
| 2023 | $3.00B | $2.80B | $-199.40M | -6.65% | -6.65% |
| 2022 | $3.02B | $3.00B | $-17.90M | -0.59% | -0.59% |
| 2021 | $1.23B | $3.02B | +$1.79B | +144.92% | +144.92% |
| 2020 | $1.80B | $1.23B | $-571.90M | -31.71% | -31.71% |
| 2019 | $2.34B | $1.80B | $-538.00M | -22.97% | -22.97% |
| 2018 | $2.06B | $2.34B | +$276.90M | +13.41% | +13.41% |
| 2017 | $2.05B | $2.06B | +$17.60M | +0.86% | +0.86% |
| 2016 | $2.01B | $2.05B | +$38.70M | +1.93% | +1.93% |
| 2015 | $1.01B | $2.01B | +$993.70M | +97.92% | +97.92% |
| 2014 | $1.11B | $1.01B | $-91.80M | -8.30% | -8.30% |
| 2013 | $949.02M | $1.11B | +$157.58M | +16.60% | +16.60% |
| 2012 | $720.42M | $949.02M | +$228.59M | +31.73% | +31.73% |
| 2011 | $931.40M | $720.42M | $-210.98M | -22.65% | -22.65% |
| 2010 | $605.08M | $931.40M | +$326.33M | +53.93% | +53.93% |
| 2009 | $384.45M | $605.08M | +$220.63M | +57.39% | +57.39% |
| 2008 | $167.69M | $384.45M | +$216.76M | +129.26% | +129.26% |
| 2007 | $416.56M | $167.69M | $-248.87M | -59.74% | -59.74% |
| 2006 | $203.71M | $416.56M | +$212.85M | +104.49% | +104.49% |
| 2005 | $225.58M | $203.71M | $-21.87M | -9.69% | -9.69% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $388.30M | -52.4% | -27.5% |
| Q4 2025 | $815.80M | +9.5% | +69.0% |
| Q3 2025 | $744.90M | +239.1% | -9.9% |
| Q2 2025 | $219.70M | -59.0% | -42.0% |
| Q1 2025 | $535.50M | +10.9% | -12.9% |
| Q4 2024 | $482.70M | -41.6% | +0.7% |
| Q3 2024 | $826.50M | +118.0% | -1.0% |
| Q2 2024 | $379.10M | -38.3% | -27.8% |
| Q1 2024 | $614.60M | +28.2% | -36.7% |
| Q4 2023 | $479.40M | -42.6% | +236.2% |
| Q3 2023 | $835.20M | +59.1% | -3.9% |
| Q2 2023 | $525.10M | -45.9% | -34.6% |
| Q1 2023 | $971.20M | +581.1% | -14.7% |
| Q4 2022 | $142.60M | -83.6% | -72.7% |
| Q3 2022 | $869.00M | +8.3% | -20.0% |
| Q2 2022 | $802.50M | -29.5% | +43.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith